Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick Lansigan

Showing results (61-70 of 87) with videos related to

Pageof 9
Sort By:
British Journal of Haematology|May 21, 2020
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapyNicole A Carreau, Philippe Armand, Reid W Merryman, et al.
British Journal of Haematology|April 20, 2018
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project NetworkMassimo Federico, Monica Bellei, Luigi Marcheselli, et al.
Blood Advances|August 30, 2024
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantationNarendranath Epperla, Ying Huang, Amanda F Cashen, et al.
British Journal of Haematology|November 5, 2019
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemiaToby A Eyre, Lindsey E Roeker, Christopher P Fox, et al.
Acta Haematologica|July 18, 2019
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE RegistryFrederick Lansigan, Steven M Horwitz, Lauren C Pinter-Brown, et al.
Cancer|January 30, 2019
The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort studySteven I Park, Steven M Horwitz, Francine M Foss, et al.
Cancer|July 28, 2017
C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapyNarendranath Epperla, Kami J Maddocks, Mohammed Salhab, et al.
Cancer|December 3, 2016
A prospective cohort study of patients with peripheral T-cell lymphoma in the United StatesKenneth R Carson, Steven M Horwitz, Lauren C Pinter-Brown, et al.
American Journal of Hematology|November 24, 2016
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapiesLuciano J Costa, Kami Maddocks, Narendranath Epperla, et al.
The Oncologist|July 29, 2020
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent TherapyNicole A Carreau, Orrin Pail, Philippe Armand, et al.
Pageof 9

Showing results (61-70 of 87) with videos related to

Sort By:
Pageof 9
British Journal of Haematology|May 21, 2020
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapyNicole A Carreau, Philippe Armand, Reid W Merryman, et al.
British Journal of Haematology|April 20, 2018
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project NetworkMassimo Federico, Monica Bellei, Luigi Marcheselli, et al.
Blood Advances|August 30, 2024
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantationNarendranath Epperla, Ying Huang, Amanda F Cashen, et al.
British Journal of Haematology|November 5, 2019
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemiaToby A Eyre, Lindsey E Roeker, Christopher P Fox, et al.
Acta Haematologica|July 18, 2019
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE RegistryFrederick Lansigan, Steven M Horwitz, Lauren C Pinter-Brown, et al.
Cancer|January 30, 2019
The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort studySteven I Park, Steven M Horwitz, Francine M Foss, et al.
Cancer|July 28, 2017
C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapyNarendranath Epperla, Kami J Maddocks, Mohammed Salhab, et al.
Cancer|December 3, 2016
A prospective cohort study of patients with peripheral T-cell lymphoma in the United StatesKenneth R Carson, Steven M Horwitz, Lauren C Pinter-Brown, et al.
American Journal of Hematology|November 24, 2016
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapiesLuciano J Costa, Kami Maddocks, Narendranath Epperla, et al.
The Oncologist|July 29, 2020
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent TherapyNicole A Carreau, Orrin Pail, Philippe Armand, et al.
Pageof 9